A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of Camrelizumab Combined with Rivoceranib Mesylate versus Investigator's Choice of Regimen in Treatment of Patients with Hepatocellular Carcinoma (HCC)
Advanced Hepatocellular Carcinoma (HCC)
DRUG: camrelizumab；Rivoceranib|DRUG: Rivoceranib|DRUG: Sorafenib|DRUG: Regorafenib
Stage I：Objective Response Rate（ORR）, 2.5 years|Stage II：Overall survival （OS）, 2.5 years
Stage I：Overall survival （OS）, 2.5 years|Adverse Events（AEs）, 2.5 years|Stage II：Objective Response Rate（ORR）, 2.5 years|Disease Control Rate（DCR）, 2.5 years|Duration of Response（DoR）, 2.5 years|Progression-Free-Survival （PFS）, 2.5 years|time to progression （TTP）, 2.5 years|Pharmacokinetics (PK) Ctrough of camrelizumab, 2.5 years|Pharmacokinetics (PK) Ctrough of Apatinib, 2.5 years|Proportion of anti- camrelizumab antibody (ADA), 2.5 years|Proportion of neutralizing antibody (Nab), 2.5 years
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of Camrelizumab Combined with Rivoceranib Mesylate versus Investigator's Choice of Regimen in Treatment of Patients with Hepatocellular Carcinoma (HCC)